Advanced Solid Tumor Clinical Trials & Research at Providence Medical Group

Advanced solid tumors represent a significant challenge in oncology, characterized by their resistance to conventional therapies and their potential to metastasize, leading to poor prognosis for patients. These tumors are often defined by their stage, typically stage III or IV, indicating local invasion or distant spread. Common types include advanced stages of breast, lung, colorectal, and pancreatic cancers, among others.

Advanced solid tumors studies are a novel design in oncology clinical trials that test the effect of a drug targeting a specific mutation or molecular alteration across multiple cancer types. Unlike traditional clinical trials that focus on a single cancer type, basket studies group patients based on the presence of a particular biomarker, regardless of where the cancer originated in the body.

Key features of these studies include:

  1. Biomarker-driven approach
  2. Multiple cancer types in one trial
  3. Usually single-arm design
  4. Potential for faster drug development

These studies are particularly useful for rare cancers and for evaluating targeted therapies. They can provide valuable insights into the efficacy of a treatment across various tumor types that share a common genetic alteration.

Providence Medical Group is currently enrolling patients for the following advanced solid tumor clinical trials:

Study to Assess the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors

Treatment agent: ART0380 + Irinotecan
Physician: Ian Anderson, MD
Study Coordinator: Melissa Ulrich // melissa.ulrich@providence.org // 707-521-3830
Study Resources: Study Details | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | ClinicalTrials.gov
Sponsor: Artios Pharma Ltd.
Location: Providence Cancer Center, Santa Rosa, CA

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma

Treatment agent: VMD-928 (oral CNS-penetrant) + selective inhibitor of TrkA
Physician: Ian Anderson, MD
Study Coordinator: Melissa Ulrich // melissa.ulrich@providence.org // 707-521-3830
Study Resources: Study Details | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | ClinicalTrials.gov
Sponsor: VM Oncology, LLC
Location: Providence Cancer Center, Santa Rosa, CA

Bluestar study to test a new drug in participants with advanced or metastatic ovarian, endometrial or HER2-breast cancer

Treatment agent: AZD8205- a B7-H4 targeted antibody drug conjugate (ADC).
Physician: Ian Anderson, MD
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA

A study of Dato-Dxd as monotherapy and in combination with anti-cancer agents in patients with advanced solid tumors: AZ D926UC00001 Tropion Pan-Tumor 03.​

Treatment agent: Datopotamab Deruxtecan- an ADC comprised of a recombinant humanized anti-TROP2 IgG1 mAb
Physician: Yao Yao Pollock, MD
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 (SGN005)​

Treatment agent: Disitamab Vedotin, antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2)
Physician: Ian Anderson, MD
Study Coordinator: Teresa Lund // teresa.lund@stjoe.org // 707-521-3830
Study Resources: https://classic.clinicaltrials.gov/ct2/show/NCT06003231
Sponsor: Seagen Inc.
Location: Providence Cancer Center, Santa Rosa, CA

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)​

Treatment agent: Repotrectinib (TPX-0005) oral medication
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: https://www.clinicaltrials.gov/study/NCT03093116
Sponsor: Turning Point Therapeutics, Inc.
Location: Providence Cancer Center, Santa Rosa, CA

Study for participants with selected HER2 expressing tumors: biliary tract, bladder, endometrial, ovarian, pancreatic, and rare tumors (Destiny Pan-Tumor 2)

Treatment agent: trastuzumab deruxtecan (T-DXd)
Physician: Dr Ian Anderson
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: Study Details | A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA

A study for patients with non small cell lung cancer with c-Met Exon 14 skip mutations and c-Met dysregulation advanced solid tumors

Treatment agent: APL-101 oral capsule
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: https://classic.clinicaltrials.gov/ct2/show/NCT03175224
Sponsor: Apollomics Inc.
Location: Providence Cancer Center, Santa Rosa, CA

Our Providers

Our Locations